FR21C1042I2 - Modulateurs de transport nucleaire contenant de l'hydrazide et leurs utilisations - Google Patents

Modulateurs de transport nucleaire contenant de l'hydrazide et leurs utilisations

Info

Publication number: FR21C1042I2
Authority: FR; France
Prior art keywords: nuclear transport; containing hydrazide; transport modulators; modulators containing; hydrazide
Prior art date: 2011-07-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR21C1042C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Karyopharm Therapeutics Inc

Original Assignee

Karyopharm Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-29

Filing date

2021-09-15

Publication date

2022-09-02

2021-09-15 Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc

2021-11-19 Publication of FR21C1042I1 publication Critical patent/FR21C1042I1/fr

2022-09-02 Application granted granted Critical

2022-09-02 Publication of FR21C1042I2 publication Critical patent/FR21C1042I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

FR21C1042C 2011-07-29 2021-09-15 Modulateurs de transport nucleaire contenant de l'hydrazide et leurs utilisations Active FR21C1042I2 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201161513428P	2011-07-29	2011-07-29
US201161513432P	2011-07-29	2011-07-29
US201261610178P	2012-03-13	2012-03-13
US201261653588P	2012-05-31	2012-05-31
US201261654651P	2012-06-01	2012-06-01
PCT/US2012/048319 WO2013019548A1 (fr)	2011-07-29	2012-07-26	Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations

Publications (2)

Publication Number	Publication Date
FR21C1042I1 FR21C1042I1 (fr)	2021-11-19
FR21C1042I2 true FR21C1042I2 (fr)	2022-09-02

Family

ID=46634546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR21C1042C Active FR21C1042I2 (fr)	2011-07-29	2021-09-15	Modulateurs de transport nucleaire contenant de l'hydrazide et leurs utilisations

Country Status (36)

Country	Link
US (9)	US9079865B2 (fr)
EP (3)	EP2736887B1 (fr)
JP (3)	JP6005740B2 (fr)
KR (7)	KR102136768B1 (fr)
CN (5)	CN110372672B (fr)
AR (1)	AR087342A1 (fr)
AU (6)	AU2012290454B2 (fr)
BR (1)	BR112014001934B1 (fr)
CA (1)	CA2842362C (fr)
CL (2)	CL2014000225A1 (fr)
CO (1)	CO6960539A2 (fr)
CY (2)	CY1119783T1 (fr)
DK (2)	DK3333164T3 (fr)
EA (1)	EA201490407A1 (fr)
ES (2)	ES2954991T3 (fr)
FR (1)	FR21C1042I2 (fr)
GE (1)	GEP201706616B (fr)
HK (2)	HK1198477A1 (fr)
HR (1)	HRP20180014T1 (fr)
HU (2)	HUE036058T2 (fr)
LT (2)	LT2736887T (fr)
LU (1)	LUC00219I2 (fr)
ME (1)	ME02936B (fr)
MX (2)	MX378433B (fr)
NL (1)	NL301119I2 (fr)
NO (1)	NO2021033I1 (fr)
PE (1)	PE20141170A1 (fr)
PL (2)	PL2736887T3 (fr)
PT (1)	PT2736887T (fr)
RS (1)	RS56823B1 (fr)
SI (1)	SI2736887T1 (fr)
SM (1)	SMT201800171T1 (fr)
TW (1)	TWI574957B (fr)
UA (1)	UA115532C2 (fr)
WO (1)	WO2013019548A1 (fr)
ZA (1)	ZA201401223B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2011222531B2 (en)	2010-03-05	2015-03-26	Karyopharm Therapeutics, Inc.	Nuclear transport modulatiors and uses thereof
WO2012099807A1 (fr)	2011-01-17	2012-07-26	Karyopharm Therapeutics, Inc.	Modulateurs du transport nucléaire contenant des oléfines et leurs utilisations
RS56823B1 (sr) *	2011-07-29	2018-04-30	Karyopharm Therapeutics Inc	Modulatori nukleusnog transporta koji sadrže hidrazid i njihove upotrebe
CN103842340B (zh) *	2011-07-29	2017-09-22	卡尔约药物治疗公司	核转运调节剂及其应用
KR101629233B1 (ko)	2012-01-18	2016-06-10	(주)바이오니아	자성나노입자-SAMiRNA 복합체 및 그 제조방법
SMT201800686T1 (it)	2012-05-09	2019-01-11	Biogen Ma Inc	Modulatori di trasporto nucleare e loro usi
JO3407B1 (ar)	2012-05-31	2019-10-20	Eisai R&D Man Co Ltd	مركبات رباعي هيدرو بيرازولو بيريميدين
BR112015021985B1 (pt)	2013-03-15	2022-12-13	Global Blood Therapeutics, Inc	Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição
WO2014144772A1 (fr) *	2013-03-15	2014-09-18	Karyopharm Therapeutics Inc.	Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1
JP6730922B2 (ja) *	2013-06-21	2020-07-29	カリオファームセラピューティクス，インコーポレイテッド	核内輸送調節因子およびその使用
WO2014205393A1 (fr) *	2013-06-21	2014-12-24	Karyopharm Therapeutics Inc.	Modulateurs de transport nucléaire et leurs utilisations
EP3018210A4 (fr)	2013-07-05	2017-06-07	Bioneer Corporation	Arnsi spécifique du virus de la dengue, structure d'arn-oligo à double hélice comprenant un arnsi, et composition empêchant la prolifération du virus de la dengue comprenant la structure d'arn
EP3018208B1 (fr)	2013-07-05	2020-05-27	Bioneer Corporation	Structure oligonucléotidique améliorée de type nanoparticule présentant une efficacité élevée et son procédé de préparation
KR20150006743A (ko) *	2013-07-09	2015-01-19	(주)바이오니아	간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
EP3074007B1 (fr) *	2013-11-28	2019-07-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédé et compositions pharmaceutiques de traitement de béta-thalassémies
CN112159807A (zh)	2014-04-04	2021-01-01	柏业公司	新颖的双链寡rna和包含它的用于预防或治疗纤维化或呼吸系统疾病的药物组合物
WO2016025904A1 (fr)	2014-08-15	2016-02-18	Karyopharm Therapeutics Inc.	Formes polymorphes de selinexor
US10709706B2 (en)	2015-12-31	2020-07-14	Karopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
WO2017117529A1 (fr)	2015-12-31	2017-07-06	Karyopharm Therapeutics Inc.	Modulateurs de transport nucléaire et leurs utilisations
US11034675B2 (en)	2016-01-08	2021-06-15	Dr. Reddy's Laboratories Limited	Solid forms of Selinexor and process for their preparation
EP3241830A1 (fr)	2016-05-04	2017-11-08	Bayer CropScience Aktiengesellschaft	Derivés de bicycles condensés hétérocycliques utilisés comme pesticides
WO2018050801A1 (fr)	2016-09-16	2018-03-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes et compositions pharmaceutiques pour le traitement de la mastocytose systémique
WO2018098472A1 (fr)	2016-11-28	2018-05-31	Karyopharm Therapeutics Inc.	Inhibiteurs de crm1 pour le traitement de l'épilepsie
EP3565813A1 (fr)	2017-01-05	2019-11-13	Watson Laboratories, Inc.	Nouvelles formes cristallines de sélinexor et leur procédé de préparation
CN106831731B (zh) *	2017-01-17	2019-11-08	广州市闻皓生物科技有限公司	一种Selinexor原料药的合成方法
CN106831617A (zh) *	2017-01-17	2017-06-13	广州市闻皓生物科技有限公司	一种Selinexor中间体的合成工艺
WO2018191707A2 (fr) *	2017-04-13	2018-10-18	Brown University	Régulateur nucléocytoplasmique de facteurs de transcription associés à l'autophagie
WO2019232724A1 (fr)	2018-06-06	2019-12-12	Xw Laboratories, Inc.	Composés en tant que modulateurs de transport nucléaire et leurs utilisations
CN108947982A (zh) *	2018-08-16	2018-12-07	刘璐	治疗非酒精性脂肪肝病的吡嗪衍生物、组合物和应用
WO2020092965A1 (fr) *	2018-11-01	2020-05-07	Karyopharm Therapeutics Inc.	E2f1 en tant que biomarqueur pour des traitements utilisant des inhibiteurs de xpo1
CN111606890A (zh) *	2019-02-26	2020-09-01	微境生物医药科技(上海)有限公司	含丙烯酰基的核转运调节剂及其用途
WO2020191140A1 (fr)	2019-03-20	2020-09-24	Johnson Matthey Public Limited Company	Formes co-cristallines de selinexor
WO2020223678A1 (fr)	2019-05-01	2020-11-05	Karyopharm Therapeutics Inc.	Procédé de préparation d'inhibiteurs de xpo1 et intermédiaires destinés à être utilisés dans la préparation d'inhibiteurs de xpo1
EP3808742A1 (fr)	2019-10-16	2021-04-21	Sandoz AG	Polymorphe de selinexor
WO2021163338A1 (fr)	2020-02-11	2021-08-19	Karyopharm Therapeutics Inc.	Inhibiteurs de xpo1 destinés à être utilisés dans le traitement du cancer
CN115485272A (zh)	2020-03-27	2022-12-16	朗多生物制药股份有限公司	Plxdc2配体
WO2021202745A1 (fr)	2020-03-31	2021-10-07	Karyopharm Therapeutics Inc.	Traitement du covid-19 à l'aide d'un composé sine
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021252874A1 (fr)	2020-06-11	2021-12-16	Karyopharm Therapeutics Inc.	Inhibiteurs de xpo1 destinés à être utilisés dans le traitement du cancer
WO2021252900A1 (fr)	2020-06-11	2021-12-16	Karyopharm Therapeutics Inc.	Biomarqueurs pour la réponse à des inhibiteurs de l'exportine 1 chez des patients atteints d'un myélome multiple
WO2021252905A1 (fr)	2020-06-11	2021-12-16	Karyopharm Therapeutics Inc.	Biomarqueurs pour la réponse à des inhibiteurs de l'exportine 1 chez des patients atteints d'un lymphome diffus à grandes cellules b
US20230391754A1 (en)	2020-10-21	2023-12-07	Karyopharm Therapeutics Inc.	Crystalline form of selinexor
CN112679477B (zh) *	2020-12-17	2021-10-26	佛山奕安赛医药科技有限公司	塞利尼索及其中间体的制备方法
WO2022143779A1 (fr) *	2020-12-29	2022-07-07	南京明德新药研发有限公司	Composé contenant un alcényle et son application
WO2022232417A1 (fr)	2021-04-28	2022-11-03	Karyopharm Therapeutics Inc.	Biomarqueurs pour la réponse à des inhibiteurs de l'exportine 1 chez des patients atteints d'un myélome multiple
WO2022246065A1 (fr)	2021-05-19	2022-11-24	Karyopharm Therapeutics Inc.	Biomarqueur calb1 utilisé dans le traitement de liposarcome dé-différencié à l'aide d'inhibiteurs de xpo1, tels que le sélinexor
TWI857509B (zh) *	2022-03-07	2024-10-01	高雄醫學大學	用於治療ｂ型肝炎病毒感染的方法
CN116514773B (zh) *	2023-04-24	2024-12-03	重庆汉佩生物科技有限公司	一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1017398A (en)	1911-01-16	1912-02-13	John E Folsom	Telegraph-key.
JPS5661360A (en) *	1979-10-25	1981-05-26	Teijin Ltd	1-substituted imidazole derivative and its preparation
KR840000529A (ko)	1981-07-07	1984-02-25	콘스탄틴 루이스 클레멘트	인돌 유도체의 제조방법
CS229934B2 (en)	1981-07-07	1984-07-16	Pfizer	Production method subst.indolylacryte acid derivative
US4778796A (en)	1985-07-19	1988-10-18	Dainippon Pharmaceutical Co., Ltd.	ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja)	1990-02-23	2000-11-20	武田薬品工業株式会社	縮合チアゾール化合物
IL97249A (en) *	1990-02-23	1995-01-24	Takeda Chemical Industries Ltd	Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en)	1993-06-24	1996-07-30	Eisai Co., Ltd.	Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en)	1994-05-05	1995-11-21	Minnesota Mining And Manufacturing Company	Mist suppressant for solvent extraction metal electrowinning
AU4368996A (en)	1994-11-23	1996-06-17	Neurogen Corporation	Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) *	1995-06-07	2003-01-23	Neurogen Corporation, Corporation Of The State Of Delaware	Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
CA2229617A1 (fr)	1995-10-20	1997-05-01	Dr. Karl Thomae Gmbh	Heterocycles a 5 chainons; medicaments a base de ces composes; leur emploi et methodes pour les preparer
CA2250002C (fr)	1996-04-04	2008-03-25	Shionogi & Co., Ltd.	Composes de cephem et medicaments contenant ces composes
AU736854B2 (en)	1996-04-25	2001-08-02	Nissan Chemical Industries Ltd.	Ethylene derivatives and pesticides containing said derivatives
JP4054992B2 (ja)	1996-04-25	2008-03-05	日産化学工業株式会社	エチレン誘導体および有害生物防除剤
DE19624659A1 (de)	1996-06-20	1998-01-08	Klinge Co Chem Pharm Fab	Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en)	1996-12-11	1999-11-30	Elan Pharmaceuticals, Inc.	Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja)	1997-12-19	2010-02-17	武田薬品工業株式会社	アニリド誘導体、その製造法および用途
WO1999050264A1 (fr)	1998-03-30	1999-10-07	Kyowa Hakko Kogyo Co., Ltd.	Derives de quinazoline
CO5271680A1 (es)	2000-02-21	2003-04-30	Smithkline Beecham Corp	Compuestos
DE60115279T2 (de)	2000-09-29	2006-12-28	Topotarget Uk Ltd., Abingdon	Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
JP3795044B2 (ja)	2001-09-14	2006-07-12	メシルジーン、インコーポレイテッド	ヒストンデアセチラーゼの阻害剤
WO2004037248A2 (fr)	2002-10-24	2004-05-06	Carex Sa	Modulation de l'activite des recepteurs actives par les proliferateurs de peroxysomes
DE10250743A1 (de)	2002-10-31	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
CN1731994A (zh) *	2002-11-01	2006-02-08	武田药品工业株式会社	预防或治疗神经病的药剂
JP4145230B2 (ja)	2002-11-01	2008-09-03	武田薬品工業株式会社	神経障害の予防・治療剤
CA2504941C (fr)	2002-11-08	2012-06-26	Neurogen Corporation	6-arylpyridines substituees en position 3
EP1599447A1 (fr)	2003-02-28	2005-11-30	Galderma Research & Development, S.N.C.	Ligands modulant des recepteurs du type lxr
KR100966749B1 (ko)	2004-05-26	2010-06-30	에자이 알앤드디 매니지먼트 가부시키가이샤	신나미드 화합물
JPWO2006016637A1 (ja)	2004-08-11	2008-05-01	杏林製薬株式会社	新規環状アミノ安息香酸誘導体
WO2006019020A1 (fr)	2004-08-16	2006-02-23	Sankyo Company, Limited	Urées de substitution
EP1849465A4 (fr)	2005-02-18	2008-12-24	Takeda Pharmaceutical	Agent de controle de la fonction du recepteur gpr34
DK1954684T3 (da)	2005-11-15	2014-06-30	Otsuka Pharma Co Ltd	Oxazol forbindelse og farmaceutisk sammensætning.
JP2007210929A (ja)	2006-02-09	2007-08-23	Sankyo Co Ltd	ウレア化合物を含有する医薬
CA2643796A1 (fr)	2006-03-09	2007-09-13	Eisai R & D Management Co., Ltd.	Derive polycyclique de cinnamide
CN101466670B (zh)	2006-04-07	2013-04-17	梅特希尔基因公司	组蛋白脱乙酰酶抑制剂
EP2014652B1 (fr)	2006-04-18	2014-08-06	Nippon Chemiphar Co., Ltd.	Agent d'activation du récepteur activé par les proliférateurs des peroxisomes
DE102006024024A1 (de) *	2006-05-23	2007-11-29	Bayer Healthcare Aktiengesellschaft	Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
US8653115B2 (en)	2006-06-13	2014-02-18	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
CN100503571C (zh)	2006-07-12	2009-06-24	中国药科大学	四氢异喹啉类衍生物、其制备方法及其医药用途
AU2007277519B2 (en)	2006-07-27	2011-12-22	Amorepacific Corporation	Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US8273738B2 (en)	2006-09-05	2012-09-25	Kyowa Hakko Kirin Co., Ltd.	Imidazole derivatives
EP1942104A1 (fr)	2006-12-20	2008-07-09	sanofi-aventis	Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique
EP1939180A1 (fr)	2006-12-20	2008-07-02	sanofi-aventis	Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale
US7795457B2 (en)	2007-02-26	2010-09-14	Kosan Biosciences Incorporated	Carbamate compounds
EP2003118A1 (fr)	2007-06-13	2008-12-17	Bayer Schering Pharma Aktiengesellschaft	Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2
TW201011003A (en)	2008-08-08	2010-03-16	Synta Pharmaceuticals Corp	Triazole compounds that modulate HSP90 activity
MX2012000434A (es)	2009-07-09	2012-04-11	Crescendo Therapeutics Llc	Metodo de sanacion de herida y modulacion de cicatriz.
WO2011069039A1 (fr)	2009-12-04	2011-06-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Composés d'hydrazone et de diacylhydrazine, et leurs procédés d'utilisation
AU2011222531B2 (en) *	2010-03-05	2015-03-26	Karyopharm Therapeutics, Inc.	Nuclear transport modulatiors and uses thereof
WO2012099807A1 (fr)	2011-01-17	2012-07-26	Karyopharm Therapeutics, Inc.	Modulateurs du transport nucléaire contenant des oléfines et leurs utilisations
CN103842340B (zh)	2011-07-29	2017-09-22	卡尔约药物治疗公司	核转运调节剂及其应用
RS56823B1 (sr)	2011-07-29	2018-04-30	Karyopharm Therapeutics Inc	Modulatori nukleusnog transporta koji sadrže hidrazid i njihove upotrebe
WO2013020024A2 (fr)	2011-08-03	2013-02-07	Karyopharm Therapeutics, Inc.	Composés de maléimide et méthodes de traitement
SMT201800686T1 (it)	2012-05-09	2019-01-11	Biogen Ma Inc	Modulatori di trasporto nucleare e loro usi
WO2014144772A1 (fr)	2013-03-15	2014-09-18	Karyopharm Therapeutics Inc.	Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1
WO2014152263A1 (fr)	2013-03-15	2014-09-25	Karyopharm Therapeutics Inc.	Modulateurs de transport nucléaire contenant une exo-oléfine et leurs utilisations
WO2014205393A1 (fr)	2013-06-21	2014-12-24	Karyopharm Therapeutics Inc.	Modulateurs de transport nucléaire et leurs utilisations
JP6730922B2 (ja)	2013-06-21	2020-07-29	カリオファームセラピューティクス，インコーポレイテッド	核内輸送調節因子およびその使用
WO2015073908A1 (fr)	2013-11-15	2015-05-21	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Procédé de sélection d'un schéma de traitement du cancer
US9828373B2 (en)	2014-07-26	2017-11-28	Sunshine Lake Pharma Co., Ltd.	2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
WO2016025904A1 (fr)	2014-08-15	2016-02-18	Karyopharm Therapeutics Inc.	Formes polymorphes de selinexor
WO2017117529A1 (fr)	2015-12-31	2017-07-06	Karyopharm Therapeutics Inc.	Modulateurs de transport nucléaire et leurs utilisations
US10709706B2 (en)	2015-12-31	2020-07-14	Karopharm Therapeutics Inc.	Nuclear transport modulators and uses thereof
US11034675B2 (en)	2016-01-08	2021-06-15	Dr. Reddy's Laboratories Limited	Solid forms of Selinexor and process for their preparation
JP6765198B2 (ja)	2016-03-10	2020-10-07	パナソニック株式会社	潜熱蓄熱材及びそれを用いる蓄熱システム
WO2018098472A1 (fr)	2016-11-28	2018-05-31	Karyopharm Therapeutics Inc.	Inhibiteurs de crm1 pour le traitement de l'épilepsie
EP3565813A1 (fr)	2017-01-05	2019-11-13	Watson Laboratories, Inc.	Nouvelles formes cristallines de sélinexor et leur procédé de préparation

2012
- 2012-07-26 RS RS20171350A patent/RS56823B1/sr unknown
- 2012-07-26 KR KR1020197011563A patent/KR102136768B1/ko active Active
- 2012-07-26 KR KR1020257000206A patent/KR20250008805A/ko active Pending
- 2012-07-26 MX MX2017002113A patent/MX378433B/es unknown
- 2012-07-26 LT LTEP12743846.3T patent/LT2736887T/lt unknown
- 2012-07-26 KR KR1020237008529A patent/KR20230042129A/ko not_active Ceased
- 2012-07-26 UA UAA201401886A patent/UA115532C2/uk unknown
- 2012-07-26 KR KR1020147005654A patent/KR102022716B1/ko active Active
- 2012-07-26 EP EP12743846.3A patent/EP2736887B1/fr active Active
- 2012-07-26 GE GEAP201213396A patent/GEP201706616B/en unknown
- 2012-07-26 SI SI201231147T patent/SI2736887T1/en unknown
- 2012-07-26 ES ES17189480T patent/ES2954991T3/es active Active
- 2012-07-26 KR KR1020247013182A patent/KR20240060688A/ko not_active Ceased
- 2012-07-26 AU AU2012290454A patent/AU2012290454B2/en active Active
- 2012-07-26 EP EP23162715.9A patent/EP4234545A3/fr active Pending
- 2012-07-26 BR BR112014001934-7A patent/BR112014001934B1/pt active IP Right Grant
- 2012-07-26 CN CN201910730981.8A patent/CN110372672B/zh active Active
- 2012-07-26 WO PCT/US2012/048319 patent/WO2013019548A1/fr active Application Filing
- 2012-07-26 AR ARP120102724A patent/AR087342A1/es active IP Right Grant
- 2012-07-26 EP EP17189480.1A patent/EP3333164B1/fr active Active
- 2012-07-26 CN CN201280047939.2A patent/CN103874690B/zh active Active
- 2012-07-26 JP JP2014522997A patent/JP6005740B2/ja active Active
- 2012-07-26 CA CA2842362A patent/CA2842362C/fr active Active
- 2012-07-26 MX MX2014001181A patent/MX349712B/es active IP Right Grant
- 2012-07-26 HU HUE12743846A patent/HUE036058T2/hu unknown
- 2012-07-26 CN CN201910734865.3A patent/CN110372673B/zh active Active
- 2012-07-26 PL PL12743846T patent/PL2736887T3/pl unknown
- 2012-07-26 DK DK17189480.1T patent/DK3333164T3/da active
- 2012-07-26 EA EA201490407A patent/EA201490407A1/ru unknown
- 2012-07-26 DK DK12743846.3T patent/DK2736887T3/en active
- 2012-07-26 KR KR1020207020507A patent/KR20200088518A/ko not_active Ceased
- 2012-07-26 CN CN201610414957.XA patent/CN106083827B/zh active Active
- 2012-07-26 ES ES12743846.3T patent/ES2655645T3/es active Active
- 2012-07-26 PT PT127438463T patent/PT2736887T/pt unknown
- 2012-07-26 SM SM20180171T patent/SMT201800171T1/it unknown
- 2012-07-26 TW TW101126934A patent/TWI574957B/zh active
- 2012-07-26 CN CN202311190454.5A patent/CN117229268A/zh active Pending
- 2012-07-26 KR KR1020217019908A patent/KR20210083380A/ko not_active Ceased
- 2012-07-26 PL PL17189480.1T patent/PL3333164T3/pl unknown
- 2012-07-26 PE PE2014000139A patent/PE20141170A1/es active IP Right Grant
- 2012-07-29 US US14/235,306 patent/US9079865B2/en active Active
2014
- 2014-01-29 CL CL2014000225A patent/CL2014000225A1/es unknown
- 2014-02-18 ZA ZA2014/01223A patent/ZA201401223B/en unknown
- 2014-02-27 CO CO14041777A patent/CO6960539A2/es active IP Right Grant
- 2014-03-19 US US14/219,638 patent/US8999996B2/en active Active
- 2014-11-27 HK HK14111981.2A patent/HK1198477A1/xx unknown
2015
- 2015-05-11 CL CL2015001257A patent/CL2015001257A1/es unknown
- 2015-06-10 US US14/735,853 patent/US9206158B2/en active Active
- 2015-11-13 US US14/940,310 patent/US9714226B2/en active Active
2016
- 2016-08-04 AU AU2016210682A patent/AU2016210682B2/en active Active
- 2016-09-07 JP JP2016174614A patent/JP6309057B2/ja active Active
2017
- 2017-06-21 US US15/629,307 patent/US10173987B2/en active Active
2018
- 2018-01-04 HR HRP20180014TT patent/HRP20180014T1/hr unknown
- 2018-01-17 CY CY20181100059T patent/CY1119783T1/el unknown
- 2018-03-13 JP JP2018044974A patent/JP6675431B2/ja active Active
- 2018-04-02 ME MEP-2017-303A patent/ME02936B/fr unknown
- 2018-04-06 AU AU2018202441A patent/AU2018202441B2/en active Active
- 2018-11-28 US US16/203,181 patent/US10544108B2/en active Active
- 2018-12-10 HK HK18115824.0A patent/HK1256745A1/zh unknown
2019
- 2019-11-26 US US16/696,702 patent/US11034660B2/en active Active
2020
- 2020-05-12 AU AU2020203121A patent/AU2020203121B2/en active Active
2021
- 2021-05-14 US US17/321,029 patent/US11787771B2/en active Active
- 2021-07-30 NL NL301119C patent/NL301119I2/nl unknown
- 2021-07-30 LT LTPA2021007C patent/LTC2736887I2/lt unknown
- 2021-08-18 LU LU00219C patent/LUC00219I2/fr unknown
- 2021-08-26 HU HUS2100030C patent/HUS2100030I1/hu unknown
- 2021-09-06 NO NO2021033C patent/NO2021033I1/no unknown
- 2021-09-15 FR FR21C1042C patent/FR21C1042I2/fr active Active
- 2021-09-22 CY CY2021028C patent/CY2021028I2/el unknown
2022
- 2022-05-16 AU AU2022203265A patent/AU2022203265A1/en not_active Abandoned
2023
- 2023-09-11 US US18/244,659 patent/US20240279188A1/en active Pending
2024
- 2024-05-01 AU AU2024202868A patent/AU2024202868A1/en active Pending

Also Published As

Publication number	Publication date
BR112014001934A2 (pt)	2017-02-21
AU2012290454B2 (en)	2016-05-05
HUS2100030I1 (hu)	2021-09-28
CL2014000225A1 (es)	2014-12-05
US20200339521A1 (en)	2020-10-29
NL301119I2 (nl)	2021-09-15
EP3333164B1 (fr)	2023-06-07
AU2012290454A1 (en)	2014-03-20
SMT201800171T1 (it)	2018-07-17
AU2020203121A1 (en)	2020-05-28
JP2014521652A (ja)	2014-08-28
US9714226B2 (en)	2017-07-25
ES2954991T3 (es)	2023-11-28
CN110372673B (zh)	2023-10-03
US11787771B2 (en)	2023-10-17
AU2016210682B2 (en)	2018-04-19
LTPA2021007I1 (fr)	2021-08-25
RS56823B1 (sr)	2018-04-30
CN103874690B (zh)	2016-07-06
AU2024202868A1 (en)	2024-05-23
CN117229268A (zh)	2023-12-15
ME02936B (fr)	2018-04-20
KR102022716B1 (ko)	2019-09-18
LT2736887T (lt)	2018-02-12
KR20250008805A (ko)	2025-01-15
CN110372673A (zh)	2019-10-25
KR20240060688A (ko)	2024-05-08
EP2736887A1 (fr)	2014-06-04
JP6309057B2 (ja)	2018-04-11
NZ719623A (en)	2017-12-22
LUC00219I2 (fr)	2022-10-07
AU2018202441A1 (en)	2018-04-26
NO2021033I1 (no)	2021-09-06
NL301119I1 (fr)	2021-08-04
KR20140066179A (ko)	2014-05-30
PL2736887T3 (pl)	2018-03-30
KR20200088518A (ko)	2020-07-22
ZA201401223B (en)	2022-03-30
US20140364408A1 (en)	2014-12-11
CN106083827A (zh)	2016-11-09
CN103874690A (zh)	2014-06-18
US11034660B2 (en)	2021-06-15
KR20210083380A (ko)	2021-07-06
US20220073478A1 (en)	2022-03-10
US20180127384A1 (en)	2018-05-10
ES2655645T3 (es)	2018-02-21
MX378433B (es)	2025-03-11
EP4234545A3 (fr)	2023-09-06
HK1198477A1 (en)	2015-05-08
TWI574957B (zh)	2017-03-21
CL2015001257A1 (es)	2015-09-21
EP3333164A1 (fr)	2018-06-13
HRP20180014T1 (hr)	2018-04-20
US20160304472A1 (en)	2016-10-20
EA201490407A1 (ru)	2014-05-30
US9079865B2 (en)	2015-07-14
UA115532C2 (uk)	2017-11-27
US10544108B2 (en)	2020-01-28
US20190330164A1 (en)	2019-10-31
HUE036058T2 (hu)	2018-06-28
CO6960539A2 (es)	2014-05-30
DK2736887T3 (en)	2018-01-02
CY1119783T1 (el)	2018-06-27
US20150274698A1 (en)	2015-10-01
BR112014001934B1 (pt)	2020-12-15
KR20230042129A (ko)	2023-03-27
NZ621904A (en)	2016-05-27
PL3333164T3 (pl)	2023-12-18
WO2013019548A1 (fr)	2013-02-07
US10173987B2 (en)	2019-01-08
PT2736887T (pt)	2018-01-15
CA2842362C (fr)	2020-06-16
US20140235653A1 (en)	2014-08-21
KR20190045399A (ko)	2019-05-02
CY2021028I1 (el)	2022-03-24
CA2842362A1 (fr)	2013-02-07
AU2022203265A1 (en)	2022-06-02
TW201311666A (zh)	2013-03-16
HK1256745A1 (zh)	2019-10-04
MX349712B (es)	2017-08-09
CN110372672A (zh)	2019-10-25
JP2017036287A (ja)	2017-02-16
US20240279188A1 (en)	2024-08-22
JP6005740B2 (ja)	2016-10-12
EP2736887B1 (fr)	2017-10-18
AR087342A1 (es)	2014-03-19
JP2018111713A (ja)	2018-07-19
MX2014001181A (es)	2014-07-14
CY2021028I2 (el)	2022-03-24
US8999996B2 (en)	2015-04-07
LTC2736887I2 (fr)	2022-10-25
EP4234545A2 (fr)	2023-08-30
PE20141170A1 (es)	2014-09-16
FR21C1042I1 (fr)	2021-11-19
CN110372672B (zh)	2023-09-29
AU2020203121B2 (en)	2022-02-17
GEP201706616B (en)	2017-02-10
CN106083827B (zh)	2019-09-17
AU2016210682A1 (en)	2016-08-18
US9206158B2 (en)	2015-12-08
SI2736887T1 (en)	2018-04-30
DK3333164T3 (da)	2023-09-18
JP6675431B2 (ja)	2020-04-01
KR102136768B1 (ko)	2020-07-23
AU2018202441B2 (en)	2020-02-13

Publication	Publication Date	Title
FR21C1042I2 (fr)	2022-09-02	Modulateurs de transport nucleaire contenant de l'hydrazide et leurs utilisations
FR24C1027I1 (fr)	2024-08-30	Agents antifongiques et leurs utilisations
EP2600878A4 (fr)	2014-06-11	Lymphocytes b régulateurs et leurs utilisations
EP2683406A4 (fr)	2014-09-24	Anticorps anti-cd40 et leurs utilisations
DK3404027T3 (da)	2020-06-02	Cellekernetransportmodulatorer og anvendelser deraf
EP2882847A4 (fr)	2016-03-23	Cellules tueuses naturelles et leurs utilisations
ME03063B (fr)	2019-01-20	Inhibiteurs de ssao 3-halogénoallylamines substituées et leurs utilisations
EP2961774A4 (fr)	2016-10-26	Anticorps d'alpha-synucléine et leurs utilisations
EP2668210A4 (fr)	2015-09-02	Anticorps anti-kit et leurs utilisations
EP2705039A4 (fr)	2014-10-08	Inhibiteurs de bromodomaines et leurs utilisations
EP2792674A4 (fr)	2015-06-17	Composés d'imidazolidinedione et leurs utilisations
EP2726467A4 (fr)	2015-01-21	Inhibiteurs macrocycliques de l'enzyme de dégradation de l'insuline (ide) et leurs utilisations
EP2726103A4 (fr)	2015-06-03	Anticorps anti-properdine et leurs utilisations
EP2621955A4 (fr)	2014-03-12	Anticorps anti-ceacam6 et leurs utilisations
EP2582836A4 (fr)	2014-03-19	Modulateurs de prpk-tprkb et leurs utilisations
EP2827711A4 (fr)	2016-03-23	Inhibiteurs de bace spécifiques de l'app (asbi) et leurs utilisations
EP2771008A4 (fr)	2015-04-08	Macrocycles augmentant l'activité p53 et leurs utilisations
EP2807160A4 (fr)	2014-12-24	Composés antifibrotiques et leurs utilisations
EP2699272A4 (fr)	2014-10-15	Agents de contraste et utilisations associées
EP3581563C0 (fr)	2023-06-28	Inhibiteurs ship et leurs utilisations
FR2976579B1 (fr)	2013-07-05	Epaississants non ioniques associatifs contenant des alkyls cyclohexylols, formulations les contenant et leurs utilisations
EP2627324A4 (fr)	2014-05-07	Benzamides substitués et leurs utilisations
EP2825048A4 (fr)	2015-10-14	Cellules précurseurs d'érythrocyte modifiées et leurs utilisations
EP2714638A4 (fr)	2015-09-23	Analogues de l'hyperforine, leurs méthodes de synthèse et leurs utilisations
FR2982277B1 (fr)	2015-08-21	Cassette d'expression inductible et ses utilisations